MicroRNA involvement in the pathogenesis of neuroblastoma: Potential for microRNA mediated therapeutics

Current Pharmaceutical Design

Volumn 15, Issue 4, 2009, Pages 456-462

  Stallings, R L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

Chromosomal imbalance; MicroRNA; MYCN; Neuroblastoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 6; MICRORNA; MYCN PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; RETINOIC ACID; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR E2F3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN;

3' UNTRANSLATED REGION; ADRENERGIC SYSTEM; AGE; APOPTOSIS; CANCER CELL CULTURE; CANCER MORTALITY; CELL DIFFERENTIATION; CHILDHOOD CANCER; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME DELETION; CHROMOSOME LOSS; DISEASE COURSE; GENE AMPLIFICATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; NEUROBLASTOMA; NEUROBLASTOMA CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; STEM CELL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; TRETINOIN;

EID: 64249092932     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315837     Document Type: Review

References (52)

1. Miska, EA, Alvarez-Saavedra, E, Townsend M, Yoshii A, Sestan N, Rakic P, et al. Microarray analysis of microRNA expression in the developing mammalian brain.Genome Biol 2004; 5: R68.
2. Blenkiron C, Miska EA. miRNAs in cancer: Approaches, aetiology, diagnostics and therapy. Hum Mol Genet 2007; 16(Spec No 1): R106-13.
3. Wiemer EA. The role of MicroRNAs in cancer: No small matter. Eur J Cancer 2007; 43: 1529-44.
4. He L, He X, Lowe SW, Hannon G J. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7: 819-22.
5. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007; 6:2127-32.
6. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: Profile, profile, profile. Int J Cancer 2008; 122: 969-77.
7. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
8. Stallings RL. Are chromosomal imbalances important in cancer? Trends Genet 2007; 23: 278-83.
9. Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001; 36: 11-3.
10. Plantaz D, Vandesompele J, Van Roy, N, Lastowska M, Bown, N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001; 91: 680-6.
11. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
12. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999; 18: 4948-57.
13. Breen CJ, O'Meara A, McDermott M, Mullarkey M, Stallings RL. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000; 120: 44-9.
14. Spitz R, Hero B, Ernestus K, Berthold F. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 2003; 9: 52-8.
15. Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 1998; 23: 141-52.
16. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-53.
17. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23: 2280-99.
18. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-41.
19. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976-83.
20. McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 2004; 25: 1599-609.
21. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006; 66: 6050-62.
22. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
23. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008; 122: 699-704.
24. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337-50.
25. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005; 24: 7902-12.
26. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008; 3: E2236.
27. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33.
28. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017-22.
29. Johnson DG, Degregori J. Putting the Oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 2006; 6: 731-8.
30. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6: 735-42
31. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204-13
32. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol 2007; 17: 1298-307.
33. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582: 1564-1568.
34. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, et al. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006; 66: 3673-80.
35. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-52.
36. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-4.
37. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-43.
38. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586-93.
39. Hosoi G, Hara J, Okamura T, Osugi Y, Ishihara S, Fukuzawa M, et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 1994; 73: 3087-93.
40. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67: 8433-8.
41. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of Nmyc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985; 313: 404-6.
42. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001; 15: 867-910.
43. Truckenmiller ME, Vawter MP, Cheadle C, Coggiano M, Donovan DM, Freed WJ, et al. Gene expression profile in early stage of retinoic acid-induced differentiation of human SH-SY5Y neuroblastoma cells. Restor Neurol Neurosci 2001; 18: 67-80.
44. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 2007; 104: 7957-62.
45. Afanasyeva EA, Hotz-Wagenblatt A, Glatting KH, Westermann F. New miRNAs cloned from neuroblastoma. BMC Genomics 2008; 9: 52.
46. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318; 1931-4.
47. Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C, et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007; 131: 1273-86.
48. Manohar CF, Short ML, Nguyen A, Nguyen NN, Chagnovich D, Yang Q, et al. HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA. J Biol Chem 2002; 277: 1967-73.
49. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYCinduced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70.
50. Barbarotto E, Calin GA. Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des 2008; 14(21): 2040-50.
51. Muehlbauer PA, Spellman RA, Gunther WC, Sanok KE, Wiersch CJ, O'Lone SD, et al. Improving dose selection and identification of aneugens in the in vitro chromosome aberration test by integration of flow cytometry-based methods. Environ Mol Mutagen 2008; 49(4): 318-27.
52. Vannini N, Pfeffer U, Lorusso G, Noonan DM, Albini A. Endothelial cell aging and apoptosis in prevention and disease: E-selectin expression and modulation as a model. Curr Pharm Des 2008; 14(3): 221-5.